Chewing Gum Cuts Oral HPV by 93% in Lab Tests
Chewing Gum Cuts Oral HPV by 93% in Lab Tests
Chewing Gum Cuts Oral HPV by 93% in Lab Tests
Key points
اہم نکات
मुख्य बातें
- A bioengineered chewing gum trapped up to 93% of cancer-linked HPV in laboratory saliva samples, in a University of Pennsylvania study that still needs human trials before it means anything for patients.
- Researchers led by Henry Daniell tested extracts from a lablab-bean gum carrying the antiviral protein FRIL on samples from head and neck cancer patients, cutting HPV by 93% in saliva and 80% in oral rinses, while a second version with the peptide protegrin-1 cut two harmful bacteria by more than 99%.
- The tests were done on samples outside the body, so the team says controlled human trials must now check safety, dosing and whether the effect holds in real life.
- A bioengineered chewing gum trapped up to 93% of cancer-linked HPV in laboratory saliva samples, in a University of Pennsylvania study that still needs human trials before it means anything for patients.
- Researchers led by Henry Daniell tested extracts from a lablab-bean gum carrying the antiviral protein FRIL on samples from head and neck cancer patients, cutting HPV by 93% in saliva and 80% in oral rinses, while a second version with the peptide protegrin-1 cut two harmful bacteria by more than 99%.
- The tests were done on samples outside the body, so the team says controlled human trials must now check safety, dosing and whether the effect holds in real life.
- A bioengineered chewing gum trapped up to 93% of cancer-linked HPV in laboratory saliva samples, in a University of Pennsylvania study that still needs human trials before it means anything for patients.
- Researchers led by Henry Daniell tested extracts from a lablab-bean gum carrying the antiviral protein FRIL on samples from head and neck cancer patients, cutting HPV by 93% in saliva and 80% in oral rinses, while a second version with the peptide protegrin-1 cut two harmful bacteria by more than 99%.
- The tests were done on samples outside the body, so the team says controlled human trials must now check safety, dosing and whether the effect holds in real life.
A bioengineered chewing gum trapped up to 93% of cancer-linked HPV in laboratory saliva samples, in a University of Pennsylvania study that still needs human trials before it means anything for patients. Researchers led by Henry Daniell tested extracts from a lablab-bean gum carrying the antiviral protein FRIL on samples from head and neck cancer patients, cutting HPV by 93% in saliva and 80% in oral rinses, while a second version with the peptide protegrin-1 cut two harmful bacteria by more than 99%. The tests were done on samples outside the body, so the team says controlled human trials must now check safety, dosing and whether the effect holds in real life.
A bioengineered chewing gum trapped up to 93% of cancer-linked HPV in laboratory saliva samples, in a University of Pennsylvania study that still needs human trials before it means anything for patients. Researchers led by Henry Daniell tested extracts from a lablab-bean gum carrying the antiviral protein FRIL on samples from head and neck cancer patients, cutting HPV by 93% in saliva and 80% in oral rinses, while a second version with the peptide protegrin-1 cut two harmful bacteria by more than 99%. The tests were done on samples outside the body, so the team says controlled human trials must now check safety, dosing and whether the effect holds in real life.
A bioengineered chewing gum trapped up to 93% of cancer-linked HPV in laboratory saliva samples, in a University of Pennsylvania study that still needs human trials before it means anything for patients. Researchers led by Henry Daniell tested extracts from a lablab-bean gum carrying the antiviral protein FRIL on samples from head and neck cancer patients, cutting HPV by 93% in saliva and 80% in oral rinses, while a second version with the peptide protegrin-1 cut two harmful bacteria by more than 99%. The tests were done on samples outside the body, so the team says controlled human trials must now check safety, dosing and whether the effect holds in real life.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।